Sumatriptan
Product Images NDC 53002-1562

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 53002-1562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021562)

Sumatriptan 100 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label shows a patient pack containing 9 tablets with instructions to take as directed on the package. It includes prescription information, patient name fields, barcode, and storage instructions. The label indicates the drug is for acute migraine treatment and contains a supplement facts section stating each tablet contains 100 mg of sumatriptan.*

FDA Label Image

Lbl530022592

Sumatriptan 50mg tablets patient pack label showing a 1-pack package. The label includes directions to take as directed on the package and notes it is for the treatment of acute migraine headaches. Manufacturer is RPK Pharmaceuticals, Inc. with space for clinic name and patient name.*

FDA Label Image

Lbl530022593

Sumatriptan 25 mg tablets patient pack label from RPK Pharmaceuticals, Inc. The label states the product contains 1 pack with 4 tablets, dosed 25 mg each. It includes instructions to take as directed on the package and contains a barcode. The label is designed for treatment of acute migraine headaches, with directions to take tablets whole with water.*

FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

A line graph showing the estimated probability of response over time in minutes from the initial dose for sumatriptan at 25 mg, 50 mg, and 100 mg doses compared to placebo. The response probability increases progressively over 240 minutes, with higher doses showing greater response rates than placebo.*

FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)

A line graph showing the estimated probability of remediation or rescue over 24 hours from the initial dose for Sumatriptan at doses of 25 mg, 50 mg, 100 mg, and placebo. The vertical axis represents probability percentage, and the horizontal axis represents time in hours.*

FDA Label Image

Chemical Structure (Sumatriptan Str)

Chemical structure diagram of Sumatriptan, showing the molecular arrangement of atoms and bonds characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.